Latest Shareholder Resolutions News

Lark Distilling Co. Ltd reported a 12% increase in FY25 revenue to $15.6 million, bolstered by a strategic partnership with Seppeltsfield Wines and a successful brand restage. The company also announced a leadership change with a new CEO set to take the helm in January 2026.

QuickFee Limited reports a pivotal FY25 with strong revenue growth and positive underlying profitability, alongside a strategic sale of its US Pay Now business and a proposed capital return to shareholders.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

Platinum Capital Limited has secured an ASX waiver to extend the initial term of its new investment management agreement with L1 Capital to 10 years, pending shareholder approval at the upcoming AGM.

Australian Gold and Copper Ltd has completed its acquisition of the Browns Reef tenement package, doubling its South Cobar Project area and setting the stage for a maiden resource estimate at the Evergreen target.

AMA Group Limited reported a robust FY25 with a 38.4% rise in normalized EBITDA and significant net debt reduction, setting a confident tone for FY26. Operational improvements across key divisions underpin the company’s optimistic outlook.

TMK Energy Limited has successfully passed all resolutions at its recent General Meeting, including a significant share placement involving directors and a substantial consolidation of its capital structure.

Clara Resources upgrades the Ashford Coking Coal Project resource classification and raises $1.6 million to fund a critical drilling program, while reviewing strategic options for its Kildanga Nickel/Cobalt asset.

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Enero Group’s 2025 AGM revealed a modest revenue dip but a rise in EBITDA, driven by operational improvements and AI innovation. The company’s FY26 Q1 update signals robust momentum with margin expansion and strategic client wins.

Platinum Capital Limited’s extraordinary general meeting on 1 October 2025 saw shareholders appoint three L1 Capital nominees to the board while rejecting Wilson Asset Management’s candidates, setting the stage for a potential change in investment management.